Floatz logo

FLURBIPROFEN

Healthy Adult Participants

Institut de Recherches Internationales Servier (I.R.I.S.)Small moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Healthy Adult Participants cohort.

Asset / SponsorPhaseRating
Wellbutrin
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1CC
Omeprazole
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1CC
Rosuvastatin
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1CC
MIDAZOLAM
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1CC
REPAGLINIDE
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1CC
Vorasidenib
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1CC
Gsm-779690T
Acta Pharmaceuticals, Inc
Phase 1CC
[11c]modag-005
MODAG GmbH
Early Phase 1C

Same molecule, other indications

FLURBIPROFEN is also rated in:

Leukemia, Myeloid, AcuteDormant
CC
Indicative ·
44 / 100
View asset →
sickle cell diseaseDormant
CC
Indicative ·
40 / 100
View asset →
chronic pain syndromeDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →